The introduction of a new prescription smoking-cessation aid, varenicline, in 2006 has had no significant impact on the rate at which Americans age 18 and older successfully quit smoking, according to a new study in Tobacco Control which suggests that the primary effect of varenicline (marketed as Chantix) has only been to displace the use of older tobacco addiction therapies, such as nicotine patches and the antidepressant, bupropion (Zyban).

Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.

Seema Kumar, M.D., a pediatric endocrinologist in the Mayo Clinic Children's Center, has been studying the effects of vitamin D supplementation in children for 10 years, through four clinical trials and six published studies. To date, Dr. Kumar's team has found limited benefit from vitamin D supplements in adolescents. The latest study, Effect of Vitamin D3 Treatment on Endothelial Function in Obese Adolescents, appears online in Pediatric Obesity.

The FDA, following the advice of their advisory panel, voted yesterday to approve Addyi, aka "Female Viagra," or "Pink Viagra." Good move? Bad? Keep reading...

So, I get in a pissy mood once in a while. Before you judge, you try taking the Times Square-Grand Central Station shuttle every day. See what kind of mood you end up in:

Then I read something so infuriatingly stupid in the Huffington Post — which is of questionable value even on a good day — that my already-sour disposition headed even further south.

Adding the price tag to prescription medicines worth more than £20 in England is just a "headline grabbing gimmick" which could mislead patients into believing that cheaper drugs are less important, according to an editorial in Drug and Therapeutics Bulletin.

On July 1st this year, health secretary for England Jeremy Hunt announced plans to print the indicative cost of medicines on all packs of those worth more than £20 alongside the phrase "funded by the UK taxpayer." The initiative aims to encourage more people to take personal responsibility for the use of finite public resources, added to which the health secretary claimed that the move would help cut waste and improve patient care as more people would be inclined to take their meds.

It is hardly news when partygoers end up in the emergency room from an overdose of methylenedioxymethamphetamine (MDMA), aka ecstasy (and a whole bunch of other names, such as Molly, E, X, many others).

Rather than simply report on another recent case at a music festival in California, in which ecstasy may have been the cause of two deaths, we thought it might be more interesting to explain what ecstasy really is, and debunk the myths that surround it.

It has been 13 years since the publication of the Women’s Health Initiative (WHI) studies that examined the role of menopausal hormone replacement therapy (HRT) in prevention of cardiovascular disease. It can be argued that never before or since has a medical study generated such controversy by the media and scientific community.

To this day, the results are still being debated, reinterpreted and, in many cases, misinterpreted.

Most of us would choose to experience pleasure – however we may define it – as often as possible. The public health and criminal justice systems are set up by the government partly to shape how, when and where we find pleasure, so that we balance our enjoyment with working and paying taxes.

The more we learn about the problem of too much medicine and what’s driving it, the harder it seems to imagine effective solutions. Winding back unnecessary tests and treatments will require a raft of reforms across medical research, education and regulation.

But to enable those reforms to take root, we may need to cultivate a fundamental shift in our thinking about the limits of medicine.

It’s time to free ourselves from the dangerous fantasy that medical technology can deliver us from the realities of uncertainty, aging and death.

Loxo Oncology, Inc. and The University of Colorado Cancer Center today announced the publication of a research brief describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development. Additional contributors to the paper include the Knight Cancer Institute at Oregon Health&Science University and Foundation Medicine, Inc. (Nasdaq:FMI).